Cyclacel Novel/Novel Sequence Promising In Tough Cancers
This article was originally published in Pharmaceutical Approvals Monthly
The combination of two novel drugs from Cyclacel inflicts a form of synthetic lethality in which sapacitabine causes DNA defects, rendering tumor cells vulnerable to seliciclib, which thwarts the repair process and is lethal in its own right, the lead investigator reported April 7 at the American Association for Cancer Research meeting in Washington, D.C.
You may also be interested in...
Pediatric subcommittee of the Oncologic Drugs Advisory Committee will discuss pediatric development plans for Novartis’ CDK inhibitor LEE011 and two immune checkpoint inhibitors, Bristol’s nivolumab and Merck’s MK-3475.
Cyclacel has made progress on its pivotal trial of lead candidate sapacitabine in AML. But there are questions about its potency as a monotherapy based on an under-reported European trial in which the sapacitabine arm was stopped for futility.
Pfizer’s novel oral CDK 4/6 inhibitor PD-03392991, in combination with letrozole, delivered a statistically and clinically significant increase in median progression-free survival for women with advanced ER+/HER2- breast cancer, according to interim Phase II data presented Dec. 5 at the San Antonio Breast Cancer Symposium.